Detection and cellular localisation of the synthetic soluble macromolecular drug carrier pHPMA.
Synthetic macromolecules such as copolymers of N-(2-hydroxypropyl)methacrylamide (pHPMA) are potential carriers for the delivery of drugs owing to their ability to passively accumulate in solid tumours [enhanced permeation and retention (EPR) effect]. To gain further knowledge about the biodistribution and the cellular localisation, poly(HPMA) was prepared for labelling by introducing biotin molecules. Biotinylated pHPMA (5 mol%) was intravenously injected into tumour-bearing rats and the accumulation of biotin-pHPMA was visualised using a streptavidin-alkaline phosphatase technique at day 7 post injection. In spite of the high solubility of pHPMA copolymers and the lack of attachment to cell structures, the biotinylated polymer could be easily detected in tissues fixed in 10% paraformaldehyde-phosphate buffer at 4 degrees C for 48 h. While biotin-pHPMA could be detected intracytoplasmically in liver and spleen, a predominantly interstitial localisation was observed within the anaplastic prostate carcinoma (Dunning R3327-AT1). How biotin as a label influences the biodistribution of poly(HPMA) was assessed by scintigraphy, autoradiography and histology comparing homopolymer poly(HPMA) with biotin-pHPMA. The organ distribution patterns of the two polymers correlated well, except with respect to kidney. It is assumed that the accumulation of biotin-pHPMA in the distal tubuli is due to a biotin transporter in the brush border membrane. The technique presented is useful for a more comprehensive understanding of the biodistribution of soluble macromolecules.
Kissel
Maria
M
Department of Radiation Oncology, E0505, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. kissel@dkfz.de
Peschke
Peter
P
Subr
Vladimir
V
Ulbrich
Karel
K
Strunz
Anke M
AM
Kühnlein
Rainer
R
Debus
Jürgen
J
Friedrich
Eckhard
E
D000178:Acrylamides / Q000493:pharmacokinetics; D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D000818:Animals; D001710:Biotin / Q000493:pharmacokinetics*; D004337:Drug Carriers / Q000493:pharmacokinetics*; D004952:Esters / Q000493:pharmacokinetics*; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D046911:Macromolecular Substances; D008297:Male; D008689:Methacrylates / Q000493:pharmacokinetics*; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism* / Q000473:pathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D051381:Rats; D012016:Reference Values; D012995:Solubility; D013848:Thigh / Q000000981:diagnostic imaging / Q000473:pathology; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured; D014915:Whole-Body Counting
D000178:Acrylamides; D004337:Drug Carriers; D004952:Esters; D007457:Iodine Radioisotopes; D046911:Macromolecular Substances; D008689:Methacrylates; D019275:Radiopharmaceuticals; C447720:methacryloylglycylglycine-4-nitrophenyl ester; D001710:Biotin; C032976:N-(2-hydroxypropyl)methacrylamide